Maynard Um
-
-
-
-
-
-
-
FDA accepts BridgeBio NDA for encaleret to treat ADH1
-
-
-
-
-
-
-
Raymond James Downgrades BridgeBio Pharma (BBIO) to Market Perform
-
-
-
-
-
-
-
BridgeBio Pharma Inc. (BBIO) Misses Q1 EPS by 16c
-
-
-
-
-
-
-
TD Cowen on BridgeBio Pharma (BBIO): 'A key overhang is removed now'
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
-
-
-
-
-
-
Barclays Reiterates Overweight Rating on BridgeBio Pharma (BBIO) amid tafamidis IP trial update
-
434,145 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

